Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-10-25
1993-12-28
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514399, 514400, 514439, 546 5, 546 6, 546210, 548106, 548205, 5483355, A61K 31415, C07F 994, C07D21152, C07D23354, C07D27720
Patent
active
052739848
ABSTRACT:
The invention relates to salts formed between basic H.sub.2 -receptor antagonists and a complex of bismuth with a carboxylic acid, and solvates of such salts, excluding salts in which the basic H.sub.2 -receptor antagonist is ranitidine. Examples of suitable carboxylic acids are citric acid and tartaric acid. Examples of basic H.sub.2 -receptor antagonists are cimetidine, sufotidine famotidine and nizatidine.
The salts are useful in the treatment of gastrointestinal disorders, particularly gastroduodenal conditions. The salts show the antisecretory activity associated with the basic H.sub.2 -receptor antagonist together with antibacterial activity against Campylobacter pylori, and they also possess cytoprotective properties.
REFERENCES:
patent: 5008256 (1991-04-01), Clitherow
S. J. Konturek et al., Gut, 1987, 28, pp. 1557-1563.
S. J. Konturek et al., Scandinavian Journal of Gastroenterology 1987, 22, pp. 1059-1063.
R. Iserhard et al., Abstract of a paper given at the 20th Congress of the European Assoc. of Gastroenterology and Endoscopy, Apr. 28-30, 1988.
Lancet, (M. Guslandi, 1988, (8599), pp. 1383-1385).
M. V. Borkent et al., Gut, 1988, 29, pp. 385-389.
British Pharmaceutical Codex, 1949, "Bismuthi Carbonas" p. 150.
Salmon, P. R., Digestion, 1987, 37 (suppl. 2), 42-46.
British Pharmaceutical Codex, 1949, "Busmuthi Carbonas" 150-154 and 1183-1185.
Ward et al., Proc. Adelaide, 1979, A30 (Abstract).
Bianchi Porro et al., Scandinavian Journal of Gastroenterology, 21, supplement 122, 1986, 39-41.
Lam et al., Gut, 1984, 25, 703-706.
Glaxo Group Limited
Higel Floyd D.
LandOfFree
Salts formed between basic histamine H.sub.2 -receptor antagonis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salts formed between basic histamine H.sub.2 -receptor antagonis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salts formed between basic histamine H.sub.2 -receptor antagonis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1542856